Skip to main content
. Author manuscript; available in PMC: 2022 Jul 20.
Published in final edited form as: Nature. 2022 Jun 15;606(7916):976–983. doi: 10.1038/s41586-022-04789-9

Fig. 4. Predicting platinum sensitivity using impaired homologous recombination signatures.

Fig. 4

a: A proposed model of increasing CIN complexity for impaired homologous recombination (IHR) signatures based on the signature aetiologies. b: Results for each IHR signature after training a Cox proportional hazards model to predict overall survival across 545 ovarian cancers treated with platinum-based chemotherapy. Hazard ratios, their 95% confidence interval and Wald test significance are reported. c: A schematic of the clinical classifier built on CX3 and CX2 activities of ovarian samples with germline BRCA1 mutations. d: Results of survival analyses after applying the classifier from (c) to assign patients into predicted sensitive (plus symbol) or predicted resistant (minus symbol) groups. Each row displays results for each of the four cancer cohorts from the TCGA and PCAWG projects. Differences in median survival are indicated by the arrow, with p-values from a log-rank test appearing below (Kaplan-Meier survival analysis). Hazard ratios and their 95% confidence interval of the predicted sensitive group compared to the predicted resistant group are obtained from Cox proportional hazards models correcting for stage and age of patients. P-value represents the corresponding Wald test.